FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma By Ogkologos - August 14, 2025 567 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR COVID-19 Vaccine: Distribution and Administration January 25, 2021 FDA Approves Pembrolizumab as Adjuvant Treatment for NSCLC February 2, 2023 EMA Recommends Extension of Therapeutic Indications for Polatuzumab Vedotin April 14, 2022 Pembrolizumab Combined with Chemoradiotherapy Improves PFS in Women with Newly Diagnosed,... March 27, 2024 Load more HOT NEWS Tovorafenib Approved for Some Children with Low-Grade Glioma Toothbrushes and ctDNA: Exciting early detection concepts from new teams formed... Treatment in Breast Cancer Patients Over 70 May Be Safely Reduced Cancer Patients May Soon Be Able to Get an Entire Course...
